



Press Release

Piramal Healthcare announces Q1FY2012 results, Total operating income up by 35% to ₹ 512 crores for continuing businesses, Operating Profit was higher at ₹ 155 crores, Net Profit for the quarter up to ₹ 89 crores

Mumbai, 02 August 2011: Piramal Healthcare Limited (“PHL”, NSE: PIRHEALTH, BSE: 500302) today announced Q1 results for FY2012.

For the continuing businesses, total operating income for the quarter was up by 34.8% to ₹ 512.0 crores. The Operating Profit for the quarter was at ₹ 154.5 crores against ₹ 39.9 crores in Q1FY2011. The Operating profit margins for the quarter were higher at 30.2% against 10.5% during Q1FY2011. Net Profit for the quarter was ₹ 89.2 crores and EPS was ₹ 5.3 per share.

Pharma Solutions (CRAMS) business recorded sales of ₹ 290.2 crores during Q1FY2012 against ₹ 207.5 crores in Q1FY2011 registering growth of 39.9% over Q1FY2011. The revenues from Indian facilities recorded impressive growth of 74.7% over Q1FY2011 to ₹ 172.4 crores on the back of increased supplies to the existing contracts and commencement of supplies towards new contracts. As per United Nations Conference on Trade and Development’s (UNCTAD’s), World Investment Report, 2011, PHL ranks 5th in list of top 10 pharmaceutical contract manufacturers globally.

Revenues from Piramal Critical Care business were ₹ 91.1 crores as compared to ₹ 108.2 crores in Q1FY2011 due to deferment of sales in ROW markets. OTC & Ophthalmology sales grew by 47.8% to ₹ 55.7 crores against ₹ 37.7 crores in Q1FY2011.

Update on de-merger of NCE R&D unit of Piramal Life Sciences Limited (PLSL) into PHL:

PHL and PLSL are in receipt of requisite no-objection to the Scheme from the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited under clause 24(f) of the Listing Agreement. The Hon’ble High Court directed that meetings of equity shareholders of PLSL and PHL be convened on 9th August, 2011. Extra Ordinary General Meetings (EGMs) of both companies have also been convened on the same date after the respective Court convened meetings for seeking shareholders approval for matters connected to the Scheme.

For further information on the financials, please visit our website: www.piramalhealthcare.com

Note to the Editors:

About the Piramal Group

The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover was about US \$ 1 billion in FY2011.

About Piramal Healthcare Ltd.

Piramal Healthcare is one of India's largest healthcare companies, with a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of US\$ 454 million in FY2011. With assets across North America, Europe and Asia, Piramal Healthcare is also one of the largest custom manufacturing companies across the world. It has significant presence in the global critical space with sales of anesthesia products to over 100 countries. Recently, Piramal Healthcare has sold its domestic formulation business to Abbott for a consideration of US \$ 3.8 billion.

For investor enquiries, please contact:

Sagar Gokani / Prasad Mhatre
Investor Relations Team,
Piramal Healthcare Limited.
Tel: +91 (0) 22 3046 6474 / 6489
investor.relations@piramal.com

For media enquiries, please contact:

PIRAMAL HEALTHCARE LIMITED Ganesh Somwanshi Corporate Communications, Piramal Group. Contact: +91 22 3046 5921 ganesh.somwanshi@piramal.com	PUBLIC RELATIONS AGENCY Divya / Janhavi Hanmer MS&L. Tel: +91-22-6633 5969 Mobile: +91 9769019059 / +91 9322854508 divya.nair@hanmermsl.com janhavi.bellare@hanmermsl.com
--	--